Active Biotech : FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

   Active Biotech : FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL
            LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

CONCERTO Study Enrolling Patients Globally to Evaluate Impact of Laquinimod on
                            Disability Progression

Jerusalem, Israel  and  Lund, Sweden,  March  6, 2013  -  Teva  Pharmaceutical 
Industries Ltd.  (NYSE: TEVA)  and Active  Biotech (NASDAQ  OMX NORDIC:  ACTI) 
announced today enrollment of  the first patient in  the CONCERTO study -  the 
third Phase III  placebo-controlled study designed  to evaluate the  efficacy, 
safety and  tolerability  of  once-daily  oral  laquinimod  in  patients  with 
relapsing-remitting multiple sclerosis (RRMS). The primary outcome measure  of 
CONCERTO will be confirmed disability progression as measured by the  Expanded 
Disability Status Scale (EDSS).

"Previous Phase III  studies in  more than 2,400  people with  RRMS suggest  a 
unique  profile  of  laquinimod,  directly  affecting  the   neurodegenerative 
processes that  lead  to  disability  progression, the  main  concern  in  the 
treatment of RRMS," said CONCERTO principal investigator, Dr. Timothy Vollmer,
Professor of Neurology, University of Colorado Denver, Medical Director of the
Rocky Mountain  Multiple Sclerosis  Center, and  Co-Director of  the RMMSC  at 
Anschutz. "We are currently enrolling patients in this third pivotal study  to 
further examine the clinical benefits of laquinimod on disability progression,
the primary endpoint  of the CONCERTO  trial, and brain  atrophy, at both  the 
previously studied 0.6 mg dose, and now a higher 1.2 mg dose."

The multinational, randomized, double blind placebo-controlled study will  aim 
to enroll  approximately  1,800  patients  at more  than  300  sites  globally 
(http://clinicaltrials.gov/show/NCT01707992). Along with the primary  endpoint 
of time to confirmed disability progression,  the study will also examine  the 
impact of laquinimod on endpoints such  as percent change in brain volume  and 
other clinical and MRI markers of disease activity.

"For nearly 30 years, Teva has been  focused on improving the lives of  people 
with multiple  sclerosis  by  delivering  innovative  treatment  options  that 
address this complex disease,"  said Dr. Michael  Hayden, President of  Global 
R&D and Chief Scientific Officer at Teva Pharmaceutical Industries, Ltd.  "The 
CONCERTO  study  demonstrates   our  commitment  to   collaborating  with   MS 
communities worldwide to further develop laquinimod and address unmet  patient 
needs."

ABOUT LAQUINIMOD
Laquinimod is  an oral,  once-daily CNS-active  immunomodulator with  a  novel 
mechanism of action being developed for the treatment of MS. In animal  models 
laquinimod crosses the blood brain barrier to potentially have a direct effect
on resident  CNS  inflammation and  neurodegeneration.  The global  Phase  III 
clinical development program  evaluating oral  laquinimod in  MS includes  two 
pivotal studies, ALLEGRO and BRAVO.
In addition to the  MS clinical studies, laquinimod  is currently in  clinical 
development for Crohn's disease and Lupus.

ABOUT CONCERTO
CONCERTO  is   a   multinational,   multicenter,   randomized,   double-blind, 
parallel-group, placebo-controlled  study  followed  by  an  active  treatment 
phase, to evaluate the efficacy, safety and tolerability of two doses of  oral 
administration of laquinimod 0.6 mg/day or  1.2 mg/day in subjects with  RRMS. 
This  third  Phase   III  laquinimod   study  will   evaluate  laquinimod   in 
approximately 1,800 patients for  up to 24 months,  after which patients  will 
continue to  an active  treatment  period with  laquinimod for  additional  24 
months. The  primary outcome  measure  will be  time to  confirmed  disability 
progression as measured by  the Expanded Disability  Status Scale (EDSS).  The 
study will also examine the impact of laquinimod on endpoints such as  percent 
change in brain volume, as well as  other clinical and MRI markers of  disease 
activity.

ABOUT MULTIPLE SCLEROSIS
MS is the  leading cause  of neurological disability  in young  adults. It  is 
estimated that more than 400,000 people  in the United States are affected  by 
the disease and that  two million people may  be affected worldwide.  Multiple 
sclerosis is a  degenerative disease of  the central nervous  system in  which 
inflammation  and  axonal  damage  and  loss  result  in  the  development  of 
progressive disability.

ABOUT TEVA
Teva  Pharmaceutical  Industries  Ltd.  (NYSE:  TEVA)  is  a  leading   global 
pharmaceutical  company,  committed  to  increasing  access  to   high-quality 
healthcare by developing, producing and marketing affordable generic drugs  as 
well as  innovative and  specialty pharmaceuticals  and active  pharmaceutical 
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a  global product  portfolio of more  than 1,000  molecules and  a 
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and  women's health therapeutic  areas as well  as 
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

ABOUT ACTIVE BIOTECH
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal
phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod is in Phase II development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound 57-57 for Systemic Sclerosis. Please visit
www.activebiotech.com for more information.

Teva's Safe Harbor  Statement under  the U. S.  Private Securities  Litigation 
Reform Act of 1995:



This release contains  forward-looking statements, which  express the  current 
beliefs  and  expectations  of  management.  Such  statements  are  based   on 
management's current beliefs and  expectations and involve  a number of  known 
and unknown  risks and  uncertainties  that could  cause our  future  results, 
performance  or  achievements  to  differ  significantly  from  the   results, 
performance or  achievements  expressed  or implied  by  such  forward-looking 
statements.  Important  factors  that  could  cause  or  contribute  to   such 
differences  include  risks   relating  to:   our  ability   to  develop   and 
commercialize  additional   pharmaceutical  products,   competition  for   our 
innovative  products,   especially  Copaxone®   (including  competition   from 
innovative  orally-administered  alternatives,  as  well  as  from   potential 
purported  generic  equivalents),   competition  for   our  generic   products 
(including from other pharmaceutical  companies and as  a result of  increased 
governmental pricing pressures), competition for our specialty  pharmaceutical 
businesses, our ability to achieve expected results through our innovative R&D
efforts, the effectiveness of our patents and other protections for innovative
products, decreasing  opportunities  to  obtain U.S.  market  exclusivity  for 
significant new  generic products,  our ability  to identify,  consummate  and 
successfully integrate acquisitions,  the effects of  increased leverage as  a 
result of the acquisition of Cephalon,  the extent to which any  manufacturing 
or quality control problems damage our reputation for high quality  production 
and require costly  remediation, our potential  exposure to product  liability 
claims to the extent not  covered by insurance, increased government  scrutiny 
in both the U.S. and Europe of our agreements with brand companies,  potential 
liability for  sales  of generic  products  prior  to a  final  resolution  of 
outstanding patent litigation, including that relating to the generic  version 
of Protonix®, our exposure to  currency fluctuations and restrictions as  well 
as  credit  risks,  the  effects  of  reforms  in  healthcare  regulation  and 
pharmaceutical pricing and reimbursement, any failures to comply with  complex 
Medicare  and  Medicaid  reporting   and  payment  obligations,   governmental 
investigations into  sales  and  marketing  practices  (particularly  for  our 
specialty pharmaceutical products), uncertainties surrounding the  legislative 
and   regulatory   pathway    for   the   registration    and   approval    of 
biotechnology-based products,  adverse  effects  of  political  or  economical 
instability, major  hostilities  or  acts  of  terrorism  on  our  significant 
worldwide operations, interruptions in our  supply chain or problems with  our 
information technology systems that adversely affect our complex manufacturing
processes, any  failure  to retain  key  personnel or  to  attract  additional 
executive and managerial talent, the impact of continuing consolidation of our
distributors and  customers,  variations in  patent  laws that  may  adversely 
affect our ability to manufacture our  products in the most efficient  manner, 
potentially  significant  impairments  of  intangible  assets  and   goodwill, 
potential increases  in  tax liabilities,  the  termination or  expiration  of 
governmental programs or tax benefits,  environmental risks and other  factors 
that are  discussed in  our Annual  Report on  Form 20-F  for the  year  ended 
December 31,  2011 and  in our  other  filings with  the U.S.  Securities  and 
Exchange Commission. Forward-looking statements speak  only as of the date  on 
which they are  made and  the Company undertakes  no obligation  to update  or 
revise any forward-looking statement, whether as a result of new  information, 
future events or otherwise.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish
Securities Market Act:
This press release contains certain forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from
any future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or
publicly release any revisions to forward-looking statements to reflect
events, circumstances or changes in expectations after the date of this press
release.
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 2:00 p.m. CET on March 6, 2013.
# # #

IR         Kevin C.              United States
Contacts:  Mannix                                 (215) 591-8912
           Kristen Frank         United States                (215) 591-8908
           Tomer                 Israel  (972 (3)
           Amitai                               926-7656
PR         Hadar                 Israel         972 (3) 926-7687
Contacts   Vismunski-Weinberg
           Denise Bradley        United States                (215) 591-8974
Active     Tomas Leanderson   Active Biotech AB    +46-46-19-20-95
Biotech
           Hans Kolam   Active Biotech AB    +46-46-19-20-44

FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
HUG#1683072
 
Press spacebar to pause and continue. Press esc to stop.